AbbVie

Open: 149.39 Close: 148.78 Change: -0.61

13 lessons that an AI found about AbbVie after reading internet.

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, company, …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. (ABBV) stock price, quote, news & analysis. Use the Yes link below to take you out of the Abbvie family of websites. The inclusion of any link does not imply endorsement of the linked sites.

Today's News

AbbVie will showcase a total of 23 abstracts, including a late-breaker, with 11 oral presentations and 12 poster presentations. RINVOQ is a selective JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. AbbVie will announce its third-quarter 2023 financial results on Friday, October 27, 2023. The company will host a live webcast of the earnings conference call at 8 a.m. ET. AbbVie Inc. (ABBV) stock price, quote, news & analysis. Use the Yes link below to take you out of the Abbvie family of websites. The inclusion of any link does not imply endorsement of the linked sites. AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline. European Commission Approval of TEPKINLY for Adults with Relapsed or Refractory Diffuse Large B-cell lymphoma. At the end of 2023 the company had 1,763,968,992 shares. AbbVie has completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinsons Disease (PD) AbbVie is in the Health Care sector and Biotechnology industry. Q3 earnings are confirmed for Friday, October 27, 2023. There is no upcoming split for the company. AbbVie will announce its third-quarter 2023 financial results on October 27, 2023. The company will host a live webcast of the earnings conference call. AbbVie drug discovery and preclinical data published in the journal Nature, in partnership with the Broad Institute and Calico Life Sciences. The deal has transformed its portfolio by lowering its dependence on Humira, its flagship product. AbbVie to Host Third-Quarter 2023 Earnings Conference Call at 8 a.m. Abbvie will host a live webcast of the earnings conference call at 8:00 a.M. It will be accessible through the Investor Relations website. Immunome received an upfront payment of $30 million and will be eligible to receive additional platform access payments in the aggregate amount of up to $70 million based on AbbVies election for Immunome to continue research using its Discovery Engine. Both of AbbVies Botox franchises enjoyed solid growth in 2022. Rinvoq generated $2.52 billion in sales for the company, an improvement of 52.8 percent over the previous year. Venclexta for several forms of leukemia brought in $2.01 billion in. sales. AbbVie and Calico are currently testing the molecule and another related molecule in phase 1 clinical trials. Abbvie scientists succeeded in designing a small molecule that enters the cell and binds to the PTPN2. AbbVie will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress in Copenhagen, Denmark. The company declined to exercise the license option for Harpoon Therapeutics. AbbVie to Present at Morgan Stanley Healthcare Conference on September 6, 2023 9/6/2023 Abbvie will participate in the Morgan Stanley 21st Annual Global Healthcare Conference. The company announced 45 Scholarships to U.S. students living with chronic, Immune-Mediated Diseases.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, company, live, earnings, Abbvie, announce, October, and the most common words in the summary are: abbvie, stock, job, market, news, best, new, . One of the sentences in the summary was: Use the Yes link below to take you out of the Abbvie family of websites. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #job #market #news #best #new.